72 results about "Management of depression" patented technology

Substituted 3-pyrrolidine-indole derivatives and methods for their production. Also pharmaceutical compositions containing these compounds and the use of these substances in methods of treatment, in particular treatment of pain and / or depression.

The invention provides a compound of formula (I):wherein R1, R2, R3, and Y have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease or depression comprising administering a compound of formula I, to a mammal in need of such treatment.

A method of treating or inhibiting depression in a patient with cardiovascular disease, especially a patient suffering from coronary artery or vascular disease, the method including administering, preferably orally, to the patient a therapeutically effective amount of an essential fatty acid composition comprising preferably more than 25% by weight of eicosapentanoic acid ethyl ester (EPA), of docosahexaenoic acid ethyl ester (DHA), or of a mixture of eicosapentanoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA), especially a mixture of EPA and DHA in an EPA / DHA ratio in the range from about 0.9 to about 1.5 at a dosage of from about 0.7 g to about 6 g per day.

The invention discloses a medicine for treating depression, and a preparation method thereof. The medicine is prepared from bupleurum chinense, root of red-rooted salvia, acorus gramineus, thinleaf milkwort rootbark, zedoary, coptis chinensis, dragon bone, oyster, and chlorite schist in a certain weight part proportion; bupleurum chinense, root of red-rooted salvia, acorus gramineus, thinleaf milkwort rootbark, zedoary and coptis chinensis are extracted by a percolation method, dragon bone, oyster, and chlorite schist are extracted by a levigation method, then extracts are mixed, and mixed extracts and auxiliary materials are mixed to be prepared into any common oral formulation. The medicine has the effects of soothing the liver and regulating vital energy, activating blood and dissolving stasis, tranquilizing the mind, reducing phlegm and purging fire and the like, is used for treating liver qi stagnation, vexation and sleeplessness and other symptoms, and is also used for treating depression.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

The invention belongs to the field of medicines and relates to a dihydro isoquinoline compound and application thereof in treatment of mental disorder, related to emotion, especially depressive disorder. Shown in a structural formula I, the dihydro isoquinoline compound has good protection activity on PC12 cells damaged under the induction action of corticosterone in an in vitro experiment, which suggests that the dihydro isoquinoline compound has a function of protecting nerve cells, further experiments verify that the dihydro isoquinoline compound can effectively improve level of BNDF (brain-derived neurotrophic factor) in nerve cells, the oxidation resistance of the nerve cells can also be effectively enhanced, and growth of the nerve cells is promoted; the dihydro isoquinoline compound has potential of treating mental disorder owning to repairing and protective effect on the nerve cells, is preferable for treating emotion and cognitive mental disorders, such as depressive disorder, senile dementia, anxiety, obsession and schizophrenia and is especially preferable for treatment of depression. In vivo experiments, including forced swimming and open field experiment, the dihydro isoquinoline compound shows obvious effect of alleviating depressive state of experimental animals respectively. The formula (I) is described in the specification.

A new method is found to determine an increased risk for side effects of an SSRI treatment in a person by genotyping the person for the presence of the 102 C / C DNA sequence in the 5-HT2A receptor gene. This provides for a method to improve the treatment of an SSRI responsive disorder and in particular depression.

The invention provides an application of miR-199a-3p in sperm in preparation of a depression detection product and an anti-depression drug. According to the application, miR-199a-3p in sperms is innovatively applied to a depression detection product and an antidepressant drug, depression is detected and treated based on the specific miR-199a-3p in sperms, the depression detection product can effectively improve the accuracy of depression detection and is high in detection efficiency, and the antidepressant drug can improve the treatment effect of depression and can also improve the treatment effect of sperms. The intergenerational inheritance of depression can be effectively inhibited, and large-scale popularization and application are easy.

The invention relates to a medicine composition for treating depression and a method for preparing the medicine composition, and belongs to the field of traditional Chinese medicines. The medicine composition comprises components including, by weight, 8-12 parts of radix ginseng, 8-12 parts of radix bupleuri, 10-14 parts of radix scutellariae, 8-12 parts of rhizoma pinelliae preparatum, 8-12 partsof ramulus cinnamomi, 8-12 parts of rhizoma zingiberis, 7-9 parts of semen ziziphi spinosae, 8-12 parts of radix curcumae, 13-17 parts of ossa draconis, 13-17 parts of concha ostreae, 3-5 parts of fructus jujubae and 8-12 parts of radix glycyrrhizae preparata. Outstanding curative effects can be realized by the various components in the weight ranges. The medicine composition and the method havethe advantages that the medicine composition comprises traditional Chinese medicines such as the radix ginseng, the radix bupleuri and the radix scutellariae, the radix ginseng is sweet in taste and slightly warm in nature and mainly acts in spleens and lung channels, the radix bupleuri is bitter in taste and slightly cold in nature and has certain pharmaceutical activity for regulating immune systems, effects of tranquilizing mind and relieving pain can be realized by the radix bupleuri, effects of clearing heat, drying dampness, stopping bleeding and preventing miscarriage can be realized bythe radix scutellariae, effects of drying dampness and resolving phlegm can be realized by the rhizoma pinelliae preparatum, obvious effects for treating the depression can be realized by the ramuluscinnamomi, the rhizoma zingiberis, the semen ziziphi spinosae and the like, and the medicine composition is applied to an accumulative number of years for the time being, is used for more than 300 cases and accordingly has solid clinical foundations and theoretical foundations.

There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and / or combinations thereof, for the treatment or alleviation of depression.